Envisagenics co-founders Maria Luisa Pineda (L) and Martin Akerman
June 4, 2024 07:00 AM EDT
Financing
AI

Ex­clu­sive: In­spired by Spin­raza, start­up rais­es $25M for can­cer drug tar­gets cre­at­ed by al­ter­na­tive RNA splic­ing

Ryan Cross

Senior Science Correspondent

En­vis­agen­ics, a start­up found­ed by sci­en­tists from Cold Spring Har­bor Lab­o­ra­to­ry, has raised a $25 mil­lion se­ries B round to de­vel­op drugs for can­cer and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to lay off more em­ploy­ees in Mass­a­chu­setts

Cor­rect­ed: Boehringer In­gel­heim, Gubra put a sec­ond can­di­date in­to the obe­si­ty race

Ei­sai takes over de­vel­op­ment of ADC af­ter Bris­tol My­ers ends $650M col­lab­o­ra­tion

Lil­ly inks ra­dio­phar­ma deal with Ra­dio­net­ics, with rights to buy the biotech

FTC in­ves­ti­gates Te­va over patents, dou­bling down on 'bo­gus' Or­ange Book list­ings

UniQure sells Mass­a­chu­setts man­u­fac­tur­ing site to Genezen as it con­tin­ues to down­size

A service from the Financial Times